India To Seek More Flexible Price Controls For Essential Medicines?
Executive Summary
India’s drug price control agency has been under fire from both pharmaceutical firms and patient rights’ groups for years for different reasons. Now the watchdog may be disbanded and the number of price-controlled medicines reduced as part of a policy overhaul to make the country more investor-friendly.
You may also be interested in...
WHO Raps India’s ‘Low Level’ Public Health Care Investment
The World Health Organization's new India head says the country must hike public health care spending and stop Indians falling into poverty due to medical expenses. The call coincides with new government figures highlighting the lack of medical care access in the country.
Indian Budget: New Health Schemes But Spending Remains Tight
Indian Prime Minister Narendra Modi's government has proposed in its budget to help poor families manage "unforeseen" medical costs while keeping a tight leash on the country's overall healthcare spending, which remains among the lowest globally as a percentage of GDP.
Top US Court Lifts Discovery Stay On Price-Fixing
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.